In all patients with stage II-IIIA NSCLC, especially those with a PD-L1 expression ≥ 1%, adjuvant atezolizumab reduced the risk of recurrence or death by 34% (21% if not stratified by PD-L1 expression) compared to observation (54). Here, CD274 is linked to non-small cell lung carcinoma.